Market Closed -
Nasdaq
04:30:01 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
0.69
USD
|
+1.10%
|
|
+1.69%
|
-45.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15.56
|
7.761
|
11.95
|
2.108
|
6.082
|
3.55
|
-
|
-
|
Enterprise Value (EV)
1 |
15.56
|
7.761
|
11.95
|
2.108
|
6.082
|
3.55
|
3.55
|
3.55
|
P/E ratio
|
-1.43
x
|
-0.62
x
|
-1.32
x
|
-0.2
x
|
-0.11
x
|
-0.63
x
|
-1.53
x
|
-1.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
109
x
|
27.5
x
|
19.9
x
|
-
|
5.1
x
|
1.59
x
|
0.79
x
|
0.44
x
|
EV / Revenue
|
109
x
|
27.5
x
|
19.9
x
|
-
|
5.1
x
|
1.59
x
|
0.79
x
|
0.44
x
|
EV / EBITDA
|
-
|
-1.13
x
|
-1.52
x
|
-
|
-0.88
x
|
-0.67
x
|
-0.76
x
|
-1.02
x
|
EV / FCF
|
-
|
-1.07
x
|
-
|
-
|
-
|
-0.52
x
|
-0.63
x
|
-0.87
x
|
FCF Yield
|
-
|
-93.1%
|
-
|
-
|
-
|
-193%
|
-158%
|
-115%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5.89
|
18.7
|
50.9
|
56.8
|
4,789
|
5,145
|
-
|
-
|
Reference price
2 |
2,640
|
414.0
|
234.9
|
37.08
|
1.270
|
0.6900
|
0.6900
|
0.6900
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.143
|
0.282
|
0.6
|
-
|
1.193
|
2.239
|
4.508
|
8.114
|
EBITDA
1 |
-
|
-6.881
|
-7.841
|
-
|
-6.922
|
-5.314
|
-4.655
|
-3.491
|
EBIT
1 |
-10.29
|
-7.933
|
-8.934
|
-
|
-7.732
|
-6.192
|
-5.885
|
-4.778
|
Operating Margin
|
-7,193.71%
|
-2,813.12%
|
-1,489%
|
-
|
-648.11%
|
-276.55%
|
-130.55%
|
-58.89%
|
Earnings before Tax (EBT)
1 |
-10.02
|
-7.937
|
-8.268
|
-
|
-7.71
|
-6.621
|
-6.852
|
-6.167
|
Net income
1 |
-10.03
|
-8.373
|
-8.268
|
-9.695
|
-7.71
|
-6.621
|
-6.852
|
-6.167
|
Net margin
|
-7,013.29%
|
-2,969.15%
|
-1,378%
|
-
|
-646.27%
|
-295.71%
|
-152%
|
-76%
|
EPS
2 |
-1,846
|
-667.2
|
-177.6
|
-186.0
|
-11.51
|
-1.100
|
-0.4500
|
-0.4100
|
Free Cash Flow
1 |
-
|
-7.222
|
-
|
-
|
-
|
-6.835
|
-5.612
|
-4.082
|
FCF margin
|
-
|
-2,560.99%
|
-
|
-
|
-
|
-305.27%
|
-124.49%
|
-50.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.169
|
0.195
|
0.277
|
0.25
|
0.233
|
0.305
|
0.36
|
0.295
|
0.415
|
0.485
|
0.582
|
0.757
|
EBITDA
1 |
-2.165
|
-2.043
|
-2.277
|
-2.501
|
-1.843
|
-1.678
|
-1.746
|
-1.617
|
-1.721
|
-1.358
|
-1.203
|
-1.032
|
EBIT
1 |
-2.493
|
-2.333
|
-2.572
|
-2.619
|
-2.045
|
-2
|
-1.951
|
-1.736
|
-1.843
|
-1.604
|
-1.466
|
-1.279
|
Operating Margin
|
-1,475.15%
|
-1,196.41%
|
-928.52%
|
-1,047.6%
|
-877.68%
|
-655.74%
|
-541.94%
|
-588.47%
|
-444.1%
|
-330.72%
|
-251.89%
|
-168.96%
|
Earnings before Tax (EBT)
1 |
-2.494
|
-2.332
|
-2.569
|
-2.646
|
-2.037
|
-1.993
|
-1.947
|
-1.733
|
-1.832
|
-1.672
|
-1.638
|
-1.48
|
Net income
1 |
-2.494
|
-2.332
|
-2.569
|
-2.646
|
-2.037
|
-1.993
|
-1.947
|
-1.733
|
-1.832
|
-1.672
|
-1.638
|
-1.48
|
Net margin
|
-1,475.74%
|
-1,195.9%
|
-927.44%
|
-1,058.4%
|
-874.25%
|
-653.44%
|
-540.83%
|
-587.46%
|
-441.45%
|
-344.74%
|
-281.44%
|
-195.51%
|
EPS
2 |
-50.40
|
-45.60
|
-50.40
|
-52.80
|
-15.84
|
-8.400
|
-5.640
|
-9.540
|
-0.3600
|
-0.3200
|
-0.3200
|
-0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/12/22
|
8/11/22
|
11/14/22
|
5/11/23
|
8/10/23
|
11/9/23
|
2/21/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-7.22
|
-
|
-
|
-
|
-6.84
|
-5.61
|
-4.08
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.11
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
40.43%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/25/21
|
3/29/22
|
3/16/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
0.69
USD Average target price
3.5
USD Spread / Average Target +407.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.67% | 3.55M | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|